飛鶴(06186.HK)挫13%成交增 料中績少賺逾33%-42%
中國飛鶴(06186.HK)發盈警料中績少賺逾33%-42%,該股今早失守百天線(7.99元),低見6.93元,暫守穩5月中旬所創52周低位(6.77元),現報7.24元,挫13%,成交急增至4,031萬股。同業以藍籌蒙牛(02319.HK)沽壓較大報36.75元,續跌2.1%。
飛鶴上周五收市後發盈警預計,截至6月止中期純利按年減約33.4%-42.4%,介乎約22-25億元人民幣。期內,總收益料按年減約15%-17%介乎約95-98億元人民幣。公司解釋,中期收益減少主因是內地出生率下降及期內實施「新鮮」戰略等所致。至於利潤預期減少,主因是由於嬰幼兒配方奶粉產品收入減少所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.